340B A Critical Program for Health Centers

The 340B Drug Pricing Program is an essential source of support for Community Health Centers, allowing them to stretch increasingly scarce federal resources and reinvest in patient care. The program allows health centers to purchase outpatient drugs at significantly reduced costs. Health centers pass the savings on to their patients through reduced drug prices and invest additional savings to expand access and improve health outcomes.

Health center patients include people living with HIV, people who have lost their jobs and health insurance, and essential workers in many fields, like healthcare. The cost of medicines can easily push them into poverty, disease, or even death.

Current Threats to the 340B Program

NACHC is concerned about ongoing actions by drug companies that threaten patient access to critical medicines available through the federal 340B Program. These attacks have diverted savings away from patient care and into corporate pockets, ultimately tying the hands of health center doctors and other care providers.

Latest from NACHC about 340B

Walgreens 340B Rebate Model Pilot Update (December 20, 2025): Review critical information on Walgreens’ participation timeline for the 340B Rebate Model Pilot and how claim processing will be handled beginning January 1, 2026.

340B Rebate Model Pilot Program (December 10, 2025): Check out NACHC’s resources and webinars to make sure that your community health center is prepared for the January 1 implementation.

NACHC Letter to Senate HELP Committee Regarding 340B (October 24, 2025): View letter.

NACHC Resources Related to the New Terms and Conditions for the 330 Grant in 340B (July 31, 2025):

NACHC Letter to CMS and HRSA Regarding 340B and Rebate proposals: View letter. (June 17, 2025)

NACHC Statement: Response to Trump Administration Executive Order, “Lowering Drug Prices by Once Again Putting Americans First” (April 16, 2025)

NACHC Urges Pharmaceutical Manufacturers to Reverse Harmful Restrictions: NACHC sent letters to Alkermes, Bausch+Lomb, Eli Lilly, and Sobi. (6/28/2024)

NACHC Partnership with ASAP340B

NACHC, alongside PhRMA, formed the Alliance to Save America’s 340B Program (ASAP 340B) to work towards a congressional solution to clarify parts of the 340B program. This partnership, which also includes patient, provider, and consumer advocates, aims to ensure the 340B program supports true safety-net providers and the communities they serve. NACHC is excited to work collaboratively to find solutions for all stakeholders in the 340B program.

Learn more about ASAP 340B and the group’s policy principles.